Adnan Butt


RBC Capital Initiates Outperform on Synthetic Biologics Inc; Sees 260% Upside for the Stock

In a research report issued today, RBC Capital analyst Adnan Butt initiated coverage on shares of Synthetic Biologics Inc (NYSEMKT:SYN), with an Outperform …

Here’s Why RBC Capital Reduced Price Target For MannKind Corporation

In a research report published on Monday, RBC Capital analyst Adnan Butt reiterated an Outperform rating on shares of MannKind Corporation (NASDAQ:MNKD), but reduced the …

Analysts Bullish on XOMA Corp (XOMA) While Awaiting Trial Results

Investors are patiently awaiting the results of XOMA Corp’s (NASDAQ:XOMA) EYEGUARD B Phase III trial. Shares of the company last closed at $4.

RBC Capital Maintains Positive View of Aerie Pharmaceuticals Inc Following FDA Agreement to Change Endpoint Range for Rhopressa

RBC Capital analyst Adnan Butt weighed in with some commentary on Aerie Pharmaceuticals Inc (NASDAQ:AERI) following an FDA agreement that the company may change the primary endpoint …

RBC Capital Pounds the Table on Regeneron Pharmaceuticals Inc

RBC Capital analyst Adnan Butt was out pounding the table with Regeneron Pharmaceuticals Inc (NASDAQ:REGN), reiterating an Outperform rating on the stock and boosting the price …

RBC Capital Maintains Outperform on Regeneron Pharmaceuticals Inc Following FDA Approval Recommendation for Praluent

RBC Capital analyst Adnan Butt came out with a research report on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) following an FDA panel recommendation for the approval of Regeneron …